Tagrisso ^*

Please read and follow the information on the manufacturer’s product insert leaflet with the medication. Failure to do so can cause serious health risks. Not all possible side effects can be listed here. If you experience any of these or other unexpected side effects, consult a healthcare provider immediately.

The common adverse effects include diarrhea, stomatitis, rashes, dry or itchy skin, infections around finger or toenails causing discoloration or growth issues, and changes in the blood, including low platelet counts, low leukocyte counts, and low neutrophil counts.

There is an increased risk that a patient can develop interstitial lung disease, which is a severe lung condition that can be fatal in some cases. Symptoms include difficulty breathing, cough, and fever. Regular monitoring and checks by a physician are necessary since early diagnosis and treatment are crucial. 

If any of these or any other unusual effects are noticed, it is important to consult with the prescribing doctor immediately.

The drug is not recommended for use during pregnancy or breastfeeding due to potential risks to the fetus or infant.

Non-small-cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for about 85% of all cases.

In some cases, the gene that codes for the epidermal growth factor receptors (EGFR) undergoes a mutation, leading to an abnormal form of the receptor. This abnormal EGFR is always turned “on,” causing the cell to divide and grow uncontrollably. The mutation converts EGFR from a regular cellular component into a trigger for the development of non-small-cell lung cancer (NSCLC).

Osimertinib is a third-generation EGFR inhibitor and is often used for cases where earlier treatments have failed or where specific, resistant mutations have developed.

Not every NSCLC patient will have the EGFR mutation, and even among those who do, not everyone will respond to EGFR inhibitors. Resistance to these drugs can develop over time. 

Treating the specific genetic mutations in NSCLC, such as EGFR mutations, is critical for a tailored, effective treatment strategy. Targeted therapy offers a specialized approach that could significantly improve the prognosis.